Urgent Update of Baby Tuli Saha
Help Save Baby Tuli Saha (2 Years 6 Months) Fighting Pilocytic Astrocytoma A Brain Tumor
Baby Tuli Saha, just 2 years and 6 months old, is bravely fighting Pilocytic Astrocytoma (a brain tumor). We wish to inform you that Baby Tuli has been admitted to the hospital due to high fever and is currently under close medical observation.
This sudden complication has added to the already challenging treatment journey. The doctors are monitoring her condition carefully and have started necessary investigations and treatment.
The Total Estimated Cost : ₹5,00,000
We humbly request your continued prayers and support during this critical time. Your kind donations will help the family manage ongoing hospitalisation, medicines, and further treatment expenses. Every contribution, no matter how small, can make a life-saving difference for Baby Tuli. Thank you for standing with her in this fight.

Update - 17 December 25
The baby was admitted to the Intensive Care Unit (ICU) on 17th December at around 6:00 PM after experiencing severe weakness. Following a detailed medical evaluation, the doctors have now revised the treatment plan and introduced a new treatment protocol to better manage the condition. As a result of this updated course of treatment, the overall cost of medical care has increased.

Update - 22 December 25
Baby Tuli Saha was shifted to the general ward on 22nd December and is currently under medical supervision. At present, the doctors have not shared the next course of treatment or further protocol. We will update you immediately once we receive more information from the medical team. Your continued prayers and support are deeply appreciated during this critical phase of her recovery.

Update 24 December 25
Fighting Pilocytic Astrocytoma (Brain Tumor) Baby Tuli Saha’s chemotherapy is scheduled to begin tomorrow, 25th December 2025. Doctors have advised that if she shows good recovery and responds well to the treatment, she may be discharged soon. At present, she is under four days of close medical observation, during which her condition will be carefully monitored.

Update 10 January 26
Baby Tuli Saha attended her scheduled OPD follow-up on 08 January 2026. During the visit, she was found to be clinically stable. Importantly, there have been no further seizure episodes, which is a positive sign in her ongoing treatment journey. She is tolerating her feeds well and continues to receive regular physiotherapy along with prescribed medications. Her chemotherapy course was successfully completed on 09 January 2026 as planned. The medical team has outlined the next phase of her treatment to ensure close monitoring and continued progress. Her next treatment session is scheduled for 15 January 2026, followed by a detailed OPD visit and blood investigations on 19 January 2026. The parents have been clearly advised to seek immediate medical attention if Baby Tuli develops a fever exceeding 100.4°F, or if any concerning symptoms are observed. Strict adherence to medical advice and follow-up schedules remains crucial at this stage.

Update 14 January 26
Baby Tuli Saha (Pilocytic Astrocytoma – Brain Tumor) attended her OPD follow-up visit on 08 January 2026 and was found to be clinically stable, with no further episodes of seizures reported since the last review. She is responding well to the ongoing treatment, tolerating feeds properly, and maintaining her general condition. Along with her regular medications, she has been continuing physiotherapy as advised, which is supporting her recovery and overall strength. Her chemotherapy was successfully completed on 09 January 2026 as per the planned schedule, and doctors have advised the next treatment session on 15 January 2026 to ensure steady progress in her care. A further OPD visit has been planned on 19 January 2026, during which blood tests will be conducted for monitoring and evaluation. The parents have been clearly instructed to seek immediate medical attention if the baby develops a fever above 100.4°F or shows any signs of discomfort or worsening symptoms.

Update 17 January 26

The doctors have informed us that Baby Tuli’s nasogastric (feeding) tube has been damaged and is no longer usable. As a result, the tube will need to be safely removed under sedation, which has been scheduled for Monday, 19 January 2026. Following this, Baby Tuli is advised to be admitted on Thursday, 22 January 2026, for the insertion of a chemo port under general anesthesia. This procedure is essential to ensure safer and more effective delivery of chemotherapy going forward. Until the chemo port is placed, chemotherapy will continue through a peripheral line, as recommended by the medical team. Baby Tuli remains under close medical supervision, and all necessary precautions are being taken to ensure her comfort and safety during these procedures. We will continue to keep supporters informed about her progress.

Update 20 January 2026 As per the treating doctor’s plan, the child’s chemotherapy treatment is continuing under a daycare protocol.
Chemotherapy Schedule:
Vinblastine 3.6 mg IV diluted in normal saline will be administered as a rapid infusion on the following dates:
• 19/01/2026
• 26/01/2026
• 02/02/2026
Before each chemotherapy session, Ondansetron 2 mg IV will be administered to help prevent nausea and discomfort.
Supportive Care: Supportive medications and physiotherapy will continue as advised by the medical team to support recovery and strength.
Monitoring & Safety:
A Complete Blood Count (CBC) with differential will be monitored on alternate weeks.
The fever protocol has been advised, and immediate medical attention is required if the child’s temperature exceeds 100.4°F. The child remains under close medical supervision, and all necessary precautions are being taken to ensure safe and effective treatment. Further updates will be shared as treatment progresses.

Update 27 January 2026
The baby is admitted today on 27 January, 2026 due to high fever for medical evaluation and treatment. Baby is going through multiple tests and under medical observation. The baby will continue inpatient care and Further treatment and discharge planning will depend on clinical improvement and follow-up investigation results.